Quercetin phytosome’s senolytic advantage derives from increased tissue sequestration and intracellular aglycone release, not merely higher plasma AUC

Hypothesis

The senolytic potency of quercetin phytosome exceeds that of isoquercetin (or free quercetin) because the phytosome formulation promotes greater lymphatic uptake and tissue retention, leading to higher intracellular concentrations of quercetin aglycone within senescent cells despite comparable or only modestly elevated plasma exposure.

Mechanistic Rationale

• Lymphatic bypass: Lecithin‑based phytosomes incorporate quercetin into mixed micelles that are taken up by intestinal enterocytes via the secretory pathway, facilitating entry into the lymphatic circulation and reducing first‑pass metabolism 2. This route yields higher drug concentrations in peripheral tissues (e.g., lung, liver, adipose) where senescent cells accumulate.
• Intracellular aglycone release: Within target cells, phospholipase‑A2 hydrolyzes the phytosome complex, liberating quercetin aglycone directly into the cytosol. This avoids reliance on extracellular β‑glucuronidase activity that limits the efficacy of isoquercetin‑derived glucuronides.
• Membrane perturbation: The phospholipid carrier integrates into cellular lipid rafts, increasing membrane fluidity and facilitating passive diffusion of the aglycone into senescent cells, which often exhibit altered lipid composition.

These steps suggest that tissue‑level quercetin aglycone exposure—and thus senolytic activity—may be decoupled from plasma AUC measurements.

Testable Predictions

1. Tissue quercetin levels: After a single 500 mg oral dose, quercetin phytosome will yield ≥2‑fold higher quercetin aglycone concentrations in lung homogenates and visceral adipose tissue compared with an equimolar dose of isoquercetin, while plasma AUC₀‑₂₄ₕ differs by <1.5‑fold.
2. Senolytic biomarker reduction: In a randomized crossover trial (n = 20 healthy older adults), phytosome quercetin will produce a greater decrease in circulating SASP factors (IL‑6, MMP‑9) and a higher proportion of p16^INK4a^‑low PBMCs 24 h post‑dose than isoquercetin, despite similar plasma exposure.
3. Correlation: Individual tissue quercetin aglycone levels (measured via biopsy or surrogate imaging) will correlate strongly with senescence biomarker improvement (r > 0.6), whereas plasma AUC will show a weak or non‑significant correlation (r < 0.3).

Experimental Design (Markdown Outline)

• Study design: Double‑blind, randomized, two‑period crossover; washout ≥7 days.
• Arms: (A) Quercetin phytosome 500 mg; (B) Isoquercetin 500 mg (matched for quercetin moiety).
• Sampling: Serial plasma PK (0, 0.5, 1, 2, 4, 6, 8, 12, 24 h); optional lymph aspirate via cannulation at 4 h (subset).
• Tissue readouts: Fine‑needle aspirates of subcutaneous adipose and buccal mucosa at 4 h and 24 h for quercetin aglycone quantification (LC‑MS/MS) and senescence markers (p16^INK4a^ mRNA, SA‑β‑gal activity).
• Systemic readouts: Plasma SASP cytokine panel (IL‑6, IL‑8, MCP‑1, MMP‑9) at baseline and 24 h.
• Statistical plan: Paired t‑tests for PK and tissue concentrations; mixed‑effects models for biomarker changes; Pearson correlation between tissue quercetin and biomarker shifts.

Falsifiability

If quercetin phytosome fails to demonstrate significantly higher tissue quercetin aglycone levels or superior senescence biomarker reduction relative to isoquercetin under matched dosing, the hypothesis that its senolytic edge stems from tissue sequestration and intracellular aglycone release will be falsified. Conversely, a confirmed tissue‑centric advantage would redirect formulation optimization toward enhancing lymphatic uptake and intracellular release rather than solely chasing higher plasma AUC.